Compare · OYST vs PNT
OYST vs PNT
Side-by-side comparison of Oyster Point Pharma Inc. (OYST) and POINT Biopharma Global Inc. (PNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OYST and PNT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PNT is the larger of the two at $567.8M, about 1.9x OYST ($306.1M).
- PNT has more recent analyst coverage (13 ratings vs 3 for OYST).
- Company
- Oyster Point Pharma Inc.
- POINT Biopharma Global Inc.
- Price
- $11.16+0.00%
- $12.51+0.24%
- Market cap
- $306.1M
- $567.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 3
- 13
Oyster Point Pharma Inc.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
POINT Biopharma Global Inc.
POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.
Latest OYST
- Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
- SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form 15-12G filed by Oyster Point Pharma Inc.
- Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)
- SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form EFFECT filed by Oyster Point Pharma Inc.
- SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
- SEC Form 4 filed by Invopps Gp Iv, L.L.C.
Latest PNT
- Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
- SEC Form 15-12G filed by POINT Biopharma Global Inc.
- SEC Form EFFECT filed by POINT Biopharma Global Inc.
- SEC Form EFFECT filed by POINT Biopharma Global Inc.
- SEC Form 4 filed by Goodman Jonathan R.
- SEC Form 4 filed by Kelly Justyna
- Mccann Joe A. closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Jensen Jessica D.
- Fleshner Neil E. closing all direct ownership in the company (SEC Form 4)
- Hogue Gerald L. closing all direct ownership in the company (SEC Form 4)